**EBMT WP CAR-T studies**

**CTIWp**

How to choose the CAR-T product for our patients: A survey on the current practice within the EBMT. PI: Urban Novak.

State-of-the-art of immune monitoring procedures after CAR-T cell therapies in EBMT centres. PI: Simona Pagliuca

Management and outcomes of prolonged cytopenias after CAR-T cell treatment: a report from the CTIWp of the EBMT. PI: Florent Malard and Kordelia Barbullushi

Analysing potential factors influencing CAR-T cell manufacturing in terms of production failures and out-of-specification (OOS) products. PI: Nina Worel.

Survey on grade 3-5 ICANS after CAR-T cell therapy for Large B Cell Lymphoma (LBCL) and assessment of prevention with Levetiracetam. PI: Piera Angelillo.

Impact of antibiotic used on CAR-T cell outcomes in lymphoma.

Late effects and fertility after CAR-T cell therapy: a retrospective study on behalf of the EBMT CTIWp. PI: Giorgio Orofino.

Survey on organization and techniques in ATMP development and production facilities in Europe by DARE-NL, T2Evolve, EBMT and NXTGEN-HIGHTECH - a GoCART-coalition initiative. PI: Jürgen Kuball.

**Joint CTIWp and CMWP**

Transplant versus CAR-T cell therapy for relapsed multiple myeloma: A joint study from the CTIWp and CMWP of the EBMT. PI: Nico Gagelmann.
Joint CTIWP and ADWP

CAR-T cell therapy in autoimmune diseases as concomitant or main Indication: a 2-step Joint study on behalf of EBMT ADWP and CTIWP. PI: Raffaella Greco.

LWP

Propensity score matched analysis on the outcomes of Brexucabtagene autoleucel from ZUMA-2 study and allogeneic SCT in relapsed and refractory post-BTKI Mantle Cell Lymphoma. PI: Sascha Dietrich

Comparison of outcomes of CAR-T vs Allogeneic HCT in T-cell Histiocyte-Rich large B-Cell Lymphoma. PI: Simon Renders and Peter Dreger

A real world analysis of CAR-T cell versus allogeneic stem cell transplantation in relapsed and refractory mantle cell lymphoma. PI: Nora Liebers

IDWP

Improved outcome of COVID-19 over time in patients treated with CAR-T cell therapy. PI: Anne Spanjaart and Per Ljungman

TCWP

GvHD after donor-derived CAR-T cell Infusion post allogeneic haematopoietic stem cell transplantation. PI: Guillermo Ortí.

Survey on the current management to prevent and treat CD19+ and BCMA+ CAR-T cell therapy-related complications. PI: Olaf Penack.

Impact of body mass index on outcome of CAR-T cell therapy. PI: Christian Schultze-Florey.

CAR-T cell outcomes in patients with comorbidities. PI: Olaf Penack.

GoCART supported winning proposals

https://thegocartcoalition.com/our-work/scientific-excellence/